Literature DB >> 31104523

A critical appraisal of the use of ultrasound in hepatic steatosis.

Stefano Ballestri1, Fabio Nascimbeni2, Simonetta Lugari3, Amedeo Lonardo2, Giampiero Francica4.   

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD carries an increased risk of cardio-metabolic and liver-related events accounting for a substantial economic burden. Given that the natural history of NAFLD is critically dependent on the stage of fibrosis, non-invasively identifying the subgroup of patients at a higher risk of progressive disease is key. Areas covered: This review highlights the recent developments in the use of ultrasound-based techniques in NAFLD and their performance in predicting metabolic derangements, cardiovascular risk, and progression of liver disease, notably including diagnosis of fibrosing NASH, identification, and treatment of HCC. Expert opinion: Our ability to identify NAFLD patients and to estimate steatofibrosis with various ultrasound-based techniques has undergone tremendous progress over the last few years. However, it is more difficult to capture the inflammatory component of NASH with such ultrasound-assisted techniques. Moreover, semi-quantitative, quantitative, elastographic, and contrast-enhanced ultrasound techniques are increasingly being appreciated and made available but not all such techniques will gain success in the clinical and research area. Therefore, further research will precisely define the role of the most innovative ultrasonographic techniques, while reducing costs and increasing feasibility.

Entities:  

Keywords:  Cardio-metabolic risk; NAFLD/NASH; contrast-enhanced ultrasonography; controlled attenuation parameter; hepatic fibrosis/cirrhosis; hepatocellular carcinoma; liver stiffness measurement; metabolic derangements; portal hypertension; shear wave elastography

Mesh:

Year:  2019        PMID: 31104523     DOI: 10.1080/17474124.2019.1621164

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  11 in total

Review 1.  Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.

Authors:  Elke Roeb
Journal:  Visc Med       Date:  2021-10-26

2.  Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B.

Authors:  Yu-Ge Zhou; Ning Tian; Wei-Ning Xie
Journal:  World J Hepatol       Date:  2022-04-27

3.  Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran: A Population-Based Study.

Authors:  Masood Sepehrimanesh; Ramin Niknam; Fardad Ejtehadi; Mohammad Reza Fattahi; Alireza Safarpour
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-01       Impact factor: 3.168

Review 4.  Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD.

Authors:  Viera Kupčová; Michaela Fedelešová; Jozef Bulas; Petra Kozmonová; Ladislav Turecký
Journal:  Int J Environ Res Public Health       Date:  2019-09-24       Impact factor: 3.390

5.  HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters.

Authors:  Muhammad Masroor; Zeba Haque
Journal:  J Clin Transl Hepatol       Date:  2021-01-02

6.  Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.

Authors:  Stefano Ballestri; Alessandro Mantovani; Enrica Baldelli; Simonetta Lugari; Mauro Maurantonio; Fabio Nascimbeni; Alessandra Marrazzo; Dante Romagnoli; Giovanni Targher; Amedeo Lonardo
Journal:  Diagnostics (Basel)       Date:  2021-01-09

Review 7.  SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.

Authors:  Luigi Mirarchi; Simona Amodeo; Roberto Citarrella; Anna Licata; Maurizio Soresi; Lydia Giannitrapani
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

Review 8.  Artificial intelligence in liver ultrasound.

Authors:  Liu-Liu Cao; Mei Peng; Xiang Xie; Gong-Quan Chen; Shu-Yan Huang; Jia-Yu Wang; Fan Jiang; Xin-Wu Cui; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

9.  Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review.

Authors:  Siôn A Parry; Leanne Hodson
Journal:  Adv Ther       Date:  2020-03-07       Impact factor: 3.845

Review 10.  Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.

Authors:  Óscar Soto-Angona; Gerard Anmella; María José Valdés-Florido; Nieves De Uribe-Viloria; Andre F Carvalho; Brenda W J H Penninx; Michael Berk
Journal:  BMC Med       Date:  2020-10-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.